TDOC Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of 0.11%. Teladoc Health, Inc.'s return on equity of -15.44% beat Astrana Health, Inc.'s return on equity of 1.85%.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 88.44%. On the other hand Astrana Health, Inc. has an analysts' consensus of $35.6667 which suggests that it could grow by 79.59%. Given that Teladoc Health, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Teladoc Health, Inc. is more attractive than Astrana Health, Inc..

Teladoc Health, Inc. has a beta of 2.119, which suggesting that the stock is 111.894% more volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.555%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 104.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.33x versus 0.34x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Integrated Sciences, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of -86.61%. Teladoc Health, Inc.'s return on equity of -15.44% beat Novo Integrated Sciences, Inc.'s return on equity of -49.15%.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 88.44%. On the other hand Novo Integrated Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Teladoc Health, Inc. has higher upside potential than Novo Integrated Sciences, Inc., analysts believe Teladoc Health, Inc. is more attractive than Novo Integrated Sciences, Inc..

Teladoc Health, Inc. has a beta of 2.119, which suggesting that the stock is 111.894% more volatile than S&P 500. In comparison Novo Integrated Sciences, Inc. has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.909%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Integrated Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Novo Integrated Sciences, Inc. pays out -- of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are larger than Novo Integrated Sciences, Inc. quarterly revenues of $3.2M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Novo Integrated Sciences, Inc.'s net income of -$2.7M. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Novo Integrated Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.33x versus 0.00x for Novo Integrated Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Health Care Organization, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of 14.05%. Teladoc Health, Inc.'s return on equity of -15.44% beat Pacific Health Care Organization, Inc.'s return on equity of 11.97%.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 88.44%. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Teladoc Health, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe Teladoc Health, Inc. is more attractive than Pacific Health Care Organization, Inc..

Teladoc Health, Inc. has a beta of 2.119, which suggesting that the stock is 111.894% more volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.126, suggesting its less volatile than the S&P 500 by 87.368%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Health Care Organization, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are larger than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Pacific Health Care Organization, Inc.'s net income of $223K. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Pacific Health Care Organization, Inc.'s PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.33x versus 2.53x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

WW International has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of -38.91%. Teladoc Health, Inc.'s return on equity of -15.44% beat WW International's return on equity of --.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 88.44%. On the other hand WW International has an analysts' consensus of $1.10 which suggests that it could grow by 340.71%. Given that WW International has higher upside potential than Teladoc Health, Inc., analysts believe WW International is more attractive than Teladoc Health, Inc..

Teladoc Health, Inc. has a beta of 2.119, which suggesting that the stock is 111.894% more volatile than S&P 500. In comparison WW International has a beta of 1.298, suggesting its more volatile than the S&P 500 by 29.755%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WW International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. WW International pays out -- of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are larger than WW International quarterly revenues of $186.6M. Teladoc Health, Inc.'s net income of -$49.5M is higher than WW International's net income of -$72.6M. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while WW International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.33x versus 0.03x for WW International. Usually stocks with elevated PS ratios are considered overvalued.